A Pilot of Customized Continuous Care Management of Obesity in Pre-Diabetics
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials
| City: |
|
Palo Alto |
| State: |
|
California |
| Zip Code: |
|
94022 |
| Conditions: |
|
Obesity - Pre-diabetes - Metabolic Syndrome |
| Purpose: |
|
The purpose of the E-LITE Study is to evaluate the feasibility and potential effectiveness
of two lifestyle interventions in a community based primary care setting. The study aims to
assess how changes in diet, exercise, and behavioral self-management affect weight and
related risk factors for adults at risk for diabetes and cardiovascular disease.
|
| Study Summary: |
|
In the United States, there is an epidemic of obesity and, as a result, an epidemic of
diabetes. Obese individuals with pre-diabetes (defined as impaired fasting glucose or
impaired glucose tolerance) are at high risk for progression to diabetes. A vast majority
of these individuals also have an increased risk of cardiovascular disease because of
concomitant risk factors, such as abdominal obesity, dyslipidemia, and elevated blood
pressure. Intensive lifestyle interventions that focus on dietary change, physical
activity, and behavior modification have demonstrated efficacy in achieving and maintaining
clinically significant (>5%) weight loss in populations of patients with pre-diabetes.
However, the effectiveness, cost-effectiveness, generalizability, and sustainability of such
interventions in routine primary care settings remain unknown, and rigorous clinical
research is needed.
The primary hypothesis for the E-LITE Study is that the CM intervention will reduce BMI more
than the SM intervention, which in turn will reduce BMI more than usual care, over 15
months. Secondarily, we hypothesize that, compared with usual care, intervention
participants will be associated with greater improvements in waist circumference, lipids,
blood pressure, blood glucose, lifestyle behaviors, and psychosocial well-being. In
addition, we will examine the durability of weight loss and behavioral change in the months
after the initial 3-month intensive stage.
|
| Criteria: |
|
Inclusion Criteria:
- Ethnicity: All ethnic groups;
- Body mass index 25.0-39.9 kg/m2;
- Fasting plasma glucose between 100 and 125 mg/dL;
- Any two of the following: Waist circumference >40 inches in men, >35 inches in women
(if in Asian American ≥ 35 inches in men; ≥31 inches in women); Triglycerides >150
mg/dL; High-density lipoprotein cholesterol (HDL-C) <40 mg/dL in men, <50 mg/dL in
women; Systolic blood pressure >130 mm Hg or diastolic blood pressure >85 mm Hg.
- Having a primary care physician (PCP) at the PAMF Los Altos Center;
- Seen in primary or specialty care in the Palo Alto Region at least once in the
preceding 24 months;
- A PAMF patient for ≥ 12 months;
- Able and willing to enroll and meet the requirements of the study.
Exclusion Criteria:
- Inability to speak, read or understand English;
- No regular access to a computer with Internet and email capabilities;
- Triglycerides >400 mg/dL;
- Systolic blood pressure >160 mm Hg or diastolic blood pressure >100 mm Hg;
- Initiation or change of drug therapy for elevated blood pressure or abnormal lipid
levels within the past 3 months
- Having a medical (e.g., celiac disease) or social condition (e.g., religious beliefs)
that precludes dietary changes;
- Having a medical or physical condition that make moderate intensity physical activity
(like a brisk walk) difficult or unsafe;
- Use of weight-loss medications in the past 3 months;
- Regular use (> 5 days/month) of medications that affect appetite or weight (e.g.,
oral corticosteroids, insulin, certain oral hypoglycemics, certain antidepressants,
etc.);
- Currently enrolled in a lifestyle intervention program at PAMF or elsewhere;
- Planning to undergo a bariatric surgery during the study period;
- Diagnosis of Type 1 or Type 2 diabetes mellitus;
- Significant medical co-morbidities, including uncontrolled metabolic disorders (e.g.,
thyroid, renal, liver), heart disease, stroke, and ongoing substance abuse;
- Renal insufficiency (i.e., GFR < 60 mL/min/1.73m2)
- Diagnosis of psychiatric disorders that would limit adequate informed consent or
ability to comply with study protocol;
- Diagnosis of cancer (other than non-melanoma skin cancer) that was active or treated
with radiation or chemotherapy within the past 2 years;
- Diagnosis of a terminal illness and/or in hospice care;
- Pregnant, lactating or planning to become pregnant during the study period;
- Already enrolled or planning to enroll in a research study that would limit full
participation in this study or confound the observation and interpretation of the
study's findings;
- Family/household member of another study participant or of a study staff member;
- No longer a PAMF patient or planning to transfer care outside of PAMF during the
study period;
- Planning to move out of the area during the study period;
- PCP determination that the study is inappropriate or unsafe for the patient;
- Investigator discretion for clinical safety or protocol adherence reasons.
|
| NCT ID: |
|
NCT00842426 |
| Primary Contact: |
|
Principal Investigator
Jun Ma, M.D., Ph.D.
Palo Alto Medical Foundation
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Palo Alto, California 94022
United States
There is no listed contact information for this specific location.
Site Status: N/A |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 21, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|